

Prescription Drug Affordability Board

A Prescription Drug Affordability Board (PDAB) is an independent body with the authority to evaluate high-cost drugs and set Upper Payment Limits (UPLs) on what Illinoisans will pay. This is similar to existing state practices for utilities and insurance premiums. UPLs apply to the entire supply chain, ensuring lower costs benefit consumers.

STRUCTURE



Five Member Board

Evaluate High-Cost Drugs



Stakeholder Council

Affects Entire Supply Chain



Full-Time Staff

- New drugs: \$60,000+
- Brand name drugs with \$3,000+ increase
- Any drugs that pose affordability challenges

- Manufacturers
- Wholesalers & PBMs
- Insurers & Pharmacies

- Set fair, affordable prices
- Consider barriers to access
- Apply to all purchasers and payer reimbursements

Impact on Illinoisans

1 in 4

77%

86%

1/3

Illinois voters ration their medications by cutting pills in half or skipping doses due to high costs*

of Illinoisans are worried about affording their prescription medication*

of Illinoisans are supportive of establishing a PDAB**

of premium costs are due to high-cost prescription drugs***

*2024 Public Policy Polling

**2020 Healthcare Value Hub

***2020 CareFirst BlueCross BlueShield

Drugs don't work if people can't afford them.

Contact: Anusha Thotakura, Citizen Action/Illinois, (847) 790-2423, anusha@citizenaction-il.org

Colorado PDAB Reviewed Drugs

Colorado is the state farthest along in the PDAB implementation process and has selected its first four drugs to undergo a cost review.

Reviewed Drug	Condition Treated	Patient Count	5-Year WAC Change	Patient OOP Cost	Total Paid in 2021
Enbrel*	Rheumatoid Arthritis	1,707	36.24%	\$2,812	\$72,504,276
Genvoya	HIV	940	28.84%	\$1,293	\$27,344,595
Cosentyx	Psoriatic Arthritis/Plaque Psoriasis	456	46.94%	\$2,168	\$17,954,496
Stelara*	Psoriatic Arthritis/Crohn's Disease/Ulcerative Colitis	414	23.87%	\$1,399	\$45,794,896

*Enbrel and Stelara are also on Medicare's list of the first 10 drugs to be negotiated. Our model would allow for Upper Payment Limits to be tied directly to the federally negotiated drug prices.

How PDAB Complements Medicare Drug Price Negotiations

Our PDAB model includes a component that leverages federal Medicare negotiations by adopting Maximum Fair Prices (MFPs) set by Medicare as upper payment limits (UPLs). This extends the benefits of drug price negotiations to the 62% of Illinoisans not on Medicare, expanding as Medicare negotiates more drug prices in future years.

